DNA

Innovation Agri-Tech Group Appoints Global Sales Team To Transition Business To Revenue

Retrieved on: 
Monday, July 18, 2022
CEO, Innovation, Solution, Time, Water, Technology, DNA, Food, IAG, Oxygen, Founder, Plant, Taste, Nutrient, Soil, Sale, Sales, Agriculture

The team, which have a successful track record in the technology space, have been tasked with taking the innovative and anticipated IAG technologies to a global market, and support the business in its transition to revenue.

Key Points: 
  • The team, which have a successful track record in the technology space, have been tasked with taking the innovative and anticipated IAG technologies to a global market, and support the business in its transition to revenue.
  • IAG hand-selected the team due to their strong background in accelerating sales, and their strategies to increase a company's valuation over short period of time.
  • The sales team we've appointed will be able to strategically complement our existing team.
  • The newly appointed sales team sues a unique five-step sales methodology as part of a structured approach that has proven particularly effective with high-tech sales.

n-Lorem Foundation CEO Publishes Important Perspective in Nucleic Acid Research

Retrieved on: 
Monday, July 18, 2022
Health, Philanthropy, General Health, Pharmaceutical, Other Philanthropy, Other Science, Research, Fund Raising, Genetics, Foundation, Science, Online, Culture, Perspective, Leadership, RNA, Nucleic Acids Research, CEO, Patient, LinkedIn, Bias, Time, Department, Knowledge, Longevity, Therapy, Drug discovery, Science, Program, Technology, DNA, Twitter, Environment, Biochemistry, Hope, NAR, Research, Drug development, Ionis Pharmaceuticals, Industry, Nucleic acid, Efficiency, Instagram, ASO, YouTube, University of Texas Southwestern Medical Center, Medicine, Pharmaceutical industry, Facebook, Pharmacology

n-Lorem, a nonprofit foundation , today announced the publication of an invited perspective article authored by n-Lorem founder and CEO, Dr. Stanley Crooke, and titled Establishing an Environment in Which Rigorous Scientific Inquiry is Practiced in Nucleic Acid Research (Crooke, S.T., NAR, Advanced Online Publication, July 2022).

Key Points: 
  • n-Lorem, a nonprofit foundation , today announced the publication of an invited perspective article authored by n-Lorem founder and CEO, Dr. Stanley Crooke, and titled Establishing an Environment in Which Rigorous Scientific Inquiry is Practiced in Nucleic Acid Research (Crooke, S.T., NAR, Advanced Online Publication, July 2022).
  • n-Lorem is the first, mutational-driven, nonprofit foundation focused on meeting the challenges of some of the rarest of rare patients, nano-rare patients.
  • NAR is one of the most highly regarded scientific journals with an impact factor of 17, a reflection of the importance of this journal in the field of nucleic acid research.
  • I appreciate the interest of the journal in understanding the challenges of creating a rigorous scientific environment, said Stanley T. Crooke, M.D., Ph.D., Founder, CEO and Chairman of n-Lorem Foundation.

Illumina Announces Inaugural Illumina Genomics Forum with a Conversation with Former U.S. President Barack Obama

Retrieved on: 
Monday, July 18, 2022
Research, Cancer, LinkedIn, Care Act 2014, Agriculture, Genome, Therapy, Affordable Care Act, DNA, Twitter, Genomics, Reproductive health, Forum, NASDAQ, Infection, Instagram, Health, Diagnosis, Population health, YouTube, Q&A, SAN, Renewable energy, Medicine, Facebook, Illumina

SAN DIEGO, July 18, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that former President of the United States Barack Obama will participate in a moderated Q&A conversation at the inaugural Illumina Genomics Forum, the company's global event focused on advancing genomics-driven health. The Forum will take place in San Diego from September 28 through October 1, with virtual sessions to be held on October 4.

Key Points: 
  • The Forum will take place in San Diego from September 28 through October 1, with virtual sessions to be held on October 4.
  • President Obama will participate in a fireside chat on the evening of Wednesday, September 28.
  • Few presidents have fought for equitable, accessible, and affordable healthcare as persistently and passionately as Barack Obama," said Kathryne Reeves, Chief Marketing Officer of Illumina.
  • "The era of genomics is now and I cannot think of a more appropriate and timely keynote speaker for the inaugural Illumina Genomics Forum, as we continue advocating for expanded access to the life-saving potential of genomics."

Twist Bioscience to Report Fiscal 2022 Third Quarter Financial Results on Friday, August 5, 2022

Retrieved on: 
Monday, July 18, 2022
Research, Technology, Genetics, Other Technology, Nanotechnology, Biotechnology, Pharmaceutical, Health, Science, Other Science, Silicon, Biology, Agriculture, Engineering, Drug discovery, Telephone, Technology, Genomics, DNA, NGS, Twist Bioscience, NASDAQ, PIN, Martek Biosciences Corporation, Synthetic biology, Investor relations

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 third quarter ended June 30, 2022, before the opening of the market on Aug. 5, 2022.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 third quarter ended June 30, 2022, before the opening of the market on Aug. 5, 2022.
  • The press release with the financial results will be accessible from the companys website prior to the conference call through the Investor Relations section under the Company tab at www.twistbioscience.com .
  • The conference call will be webcast live through the Investor Relations section under the Company tab at www.twistbioscience.com .
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer

Retrieved on: 
Monday, July 18, 2022
Research, Medicare, SEC, National Collaborating Centre for Mental Health, III, News, Recurrence, National Comprehensive Cancer Network, CLIA, Incremental cost-effectiveness ratio, Patient, Risk, ISO, Clinical Laboratory, Center, Oncology, Colorectal cancer, DNA, MIBC, Genetic testing, CMS, MRD, Hematology, Carcinoma, Neoplasm, NASDAQ, Multimedia, NTRA, Bladder cancer, Veni, vidi, vici, Medicine, Laboratory, LCD, Blood, Health, Form 10-K, Diagnosis, Guideline, Journal, FDA, American Journal of Clinical Oncology, Medical device, Medical imaging, Health insurance, Dietary supplement, Natera, Nature, Cancer

"This is great news for patients with bladder cancer, who face uncertain treatment decisions throughout the patient journey," said Solomon Moshkevich, general manager of oncology at Natera.

Key Points: 
  • "This is great news for patients with bladder cancer, who face uncertain treatment decisions throughout the patient journey," said Solomon Moshkevich, general manager of oncology at Natera.
  • We look forward to working with Medicare and with the oncology community to continue incorporating Signatera MRD assessment into standard care for patients with solid tumors."
  • This decision adds to the existing Medicare coverage for Signatera in colorectal cancer and for pan-cancer immunotherapy monitoring.
  • Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.

SaaS Management & Optimization Leader Zylo Shortlisted for Two 2022 SaaS Awards

Retrieved on: 
Monday, July 18, 2022
Name, CEO, Salesforce, CIO, Verizon Media, High Alpha Research Vehicle, DNA, Adobe, Heart, Bessemer Venture Partners, IT, EMEA, Organization, Industry, Efficiency, FSF Free Software Awards, GGV, CFO, Menlo Ventures, Software as a service, Financial services, Software, Food delivery, Atlassian, The Rise and Fall of Comrade Zylo, Intuit, Hootsuite

INDIANAPOLIS, July 18, 2022 /PRNewswire-PRWeb/ -- Zylo, the world's leading SaaS management and optimization platform that enables companies to organize, optimize, and orchestrate SaaS, today announced it has been shortlisted for two SaaS Awards in the Highest Customer Satisfaction and Best SaaS Product for IT Management categories.

Key Points: 
  • INDIANAPOLIS, July 18, 2022 /PRNewswire-PRWeb/ -- Zylo , the world's leading SaaS management and optimization platform that enables companies to organize, optimize, and orchestrate SaaS, today announced it has been shortlisted for two SaaS Awards in the Highest Customer Satisfaction and Best SaaS Product for IT Management categories.
  • Zylo's enterprise SaaS management and optimization platform is the only solution that provides 100% visibility into your SaaS stack, enabling organizations to organize, optimize and orchestrate their SaaS to reduce costs, mitigate risk and drive efficiency.
  • SaaS Awards finalists will be announced on Tuesday 23 August 2022, with the ultimate category winners announced on Tuesday 13 September 2022.
  • As the world leader in SaaS Management and Optimization, Zylo enables companies to organize, optimize, and orchestrate SaaS.

Generation Bio Appoints Dannielle Appelhans to Its Board of Directors

Retrieved on: 
Monday, July 18, 2022
Rubius, Leadership, Research, University, Supply, Novartis, Eli Lilly and Company, Novartis Gene Therapies, Private Securities Litigation Reform Act, Security (finance), Communication, Mechanical engineering, Form 10-K, U.S. Securities and Exchange Commission, Annual report, GLOBE, MBA, DNA, Strategic management, McKinsey & Company, Board of directors, MIT Sloan School of Management, Board, Massachusetts Institute of Technology School of Engineering, COVID-19, Company, Eli Lilly, Generation, MIT School of Architecture and Planning, Therapy, RES, Tissue, Chris Appelhans, Pharmaceutical industry, Management, Engineering

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors.
  • Dannielle Appelhans is a tenured pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations.
  • Generation Bios aim to create novel genetic medicines for therapeutic areas previously inaccessible via conventional approaches is highly compelling, Appelhans said.
  • Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases.

Vishay Intertechnology Advances Its Executive Transition Plan

Retrieved on: 
Monday, July 18, 2022
Acquisition, CEO, Security (finance), Employment, Semiconductor, U.S. Securities and Exchange Commission, Form 10-K, Director, GLOBE, Private Securities Litigation Reform Act, Financial compensation, NYSE, DNA, Global Sales Law Project, Henrici, Telecommunication, Corporate communication, Marketing, Executive, Board of directors, Board, COVID-19, Company, Growth, Professional Football Compensation Committee, Â, VSH, Corporation, Intention, Management, Vishay Intertechnology

MALVERN, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE:VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, announced that, as part of the Board of Directors executive transition plan, three executive officers will leave the Company effective December 31, 2022 and two new executive officers have been appointed, effective January 1, 2023.

Key Points: 
  • MALVERN, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE:VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, announced that, as part of the Board of Directors executive transition plan, three executive officers will leave the Company effective December 31, 2022 and two new executive officers have been appointed, effective January 1, 2023.
  • In addition, the Boards independent Compensation Committee has approved employment agreements for the executive management team that include changes to the executive compensation programs.
  • Johan Vandoorn, Executive Vice President Chief Technical Officer; Clarence Tse, Executive Vice President and Business Head Semiconductors; and, David Valletta, Executive Vice President Global Sales will leave the Company on December 31, 2022.
  • As part of our executive transition process, the Compensation Committee also determined that it was the right time to strengthen the equity component of Vishays executive compensation incentive programs.

VivoAquatics and the VivoPoint Solution, Shortlisted for 2022 SaaS Awards

Retrieved on: 
Monday, July 18, 2022
Cloud, Cloud computing, Name, Solution, Program, DNA, Year, Extended detection and response, EMEA, Organization, Industry, FSF Free Software Awards, Software as a service, Software

LOS ANGELES, July 18, 2022  /PRNewswire-PRWeb/ --

Key Points: 
  • VivoAquatics and the VivoPoint solution, has been shortlisted in the 2022 SaaS Awards program in multiple categories.
  • VivoAquatics and the VivoPoint solution, has been shortlisted in the 2022 SaaS Awards program in the following categories
    Now in its seventh year of celebrating software innovation, the Software Awards program accepts entries worldwide, including the US, Canada, Australasia, EMEA and UK.
  • Categories for 2022 include Best Enterprise-Level SaaS and Best Data-Driven SaaS, alongside new categories including 'Most Agile or Responsive SaaS Solution of the Year'.
  • SaaS Awards finalists will be announced on Tuesday 23 August 2022, with the ultimate category winners announced on Tuesday 13 September 2022.

ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors

Retrieved on: 
Monday, July 18, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Vitae, Leadership, University, Biology, Acquisition, Entrepreneurship, Cancer, Patient, Genome, Therapy, Struggle for Rome (board game), Virology, Bayer, Allergan, Wharton School of the University of Pennsylvania, Science, Machine learning, MBA, DNA, Harvard Business School, Purdue University, Biotechnology, Board, Bristol Myers Squibb, Industry, Degenerative disease, Pharmacy, Head, Virus, Pharmaceutical industry, Management

ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced the appointment of Jeff Hatfield as Chair of the ROME Board of Directors.

Key Points: 
  • ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced the appointment of Jeff Hatfield as Chair of the ROME Board of Directors.
  • Currently serving as Chief Executive Officer of Vividion Therapeutics, Mr. Hatfield brings more than three decades of successful industry leadership across biotech and pharmaceuticals.
  • We are excited to bring Jeff on to the ROME team as the Chair of our Board of Directors.
  • Mr. Hatfield currently serves on the Board of Directors of Vir Biotechnology and is a Key Advisory Board member for Harvard Business Schools Blavatnik Fellowship in Life Science Entrepreneurship.